CEO van de Winkel wants long tenure at Genmab
Jan van de Winkel, CEO of Genmab, sees himself staying at Genmab for a long time, which the company’s chair, Deirdre P. Connelly welcomes.
by marketwire, translated by daniel pedersen
The CEO of Genmab, Jan van de Winkel, hopes to continue leading the Danish biotech giant for several years, he replied when asked about his future plans on Monday at a press event in connection with the firm’s AGM.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab nominates Eli Lilly veteran as board member
For subscribers
Genmab receives orphan drug designation from FDA
For subscribers
Genmab CEO lands USD 6.8m salary in 2021
For subscribers
